Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2003-12-17
2008-08-19
Jiang, Shaojia Anna (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S251000, C544S370000, C544S371000, C514S267000
Reexamination Certificate
active
07414058
ABSTRACT:
There is disclosed a method for the treatment of Extra Pyramidal syndrome (EPS) comprising the administration of an adenosine A2a receptor antagonist, alone or in combination with other agents useful for treating EPS.
REFERENCES:
patent: 5565460 (1996-10-01), Suzuki et al.
patent: 5935964 (1999-08-01), Baraldi et al.
patent: 6630475 (2003-10-01), Neustadt et al.
patent: WO 95/01356 (1995-01-01), None
patent: WO 99/26627 (1999-06-01), None
patent: WO 00/13682 (2000-03-01), None
patent: WO 01/02409 (2001-01-01), None
patent: WO01/92264 (2001-12-01), None
patent: WO 02/055083 (2002-07-01), None
patent: WO 02/080957 (2002-10-01), None
patent: WO 03/032996 (2003-04-01), None
patent: WO 03/048163 (2003-06-01), None
patent: WO 03/048163 (2003-06-01), None
patent: WO 03/048164 (2003-06-01), None
patent: WO 03/048165 (2003-06-01), None
patent: WO 03/063876 (2003-08-01), None
patent: WO2004/019949 (2004-03-01), None
patent: WO 2004/094431 (2004-11-01), None
The Merck Manual of Diagnosis and Therapy, Seventeenth Edition, (1999) Beers et al., eds., Published by Merck Research Laboratories, p. 1416.
Chemical Abstracts Registry No. 160098-96-4, entered into STN Jan. 12, 1995.
Andrew L. Chesson et al., “Sleep”,J. of Sleep and Sleep Disorders Research, 22(7):961-968 (1999).
Patti R. Weimerskirch et al., “Newer Dopamine Agonists in the Treatment of Restless Legs Syndrome”,The Annals of Pharmacotherapy, 35(5):627-630, 2001.
M. Saletu et al., “Sleep Laboratory Studies in Restless Legs Syndrome Patients as Compared with Normals and Acute Effects of Ropinirole”,Neuropsychobiology, 41(4):190-199, (2000).
Chartoff et al,JPET, 291 (1999), p. 531-537.
Ward et al,Neuroscience, 89, 3 (1999), p. 927-938.
Pinna et al,Neuropsychopharmacology, 20, 1 (1999), p. 44-51.
Wardas et al,Synapse, 41 (2001), p. 160-171.
Morelli et al,Neurotoxicity Res., 3, (2001), p. 545-556.
Kanda et al,Eur. J. Pharmacol., 256 (1994), p. 263-268.
Kuwana et al,Abstracts of the Society for Neuroscience, 23 (1997), p. 297 (abstract 119-14).
Shiozaki et al,Psychopharmacology, 147 (1999), p. 90-95.
Adami et al,Brit. J. Pharmacol., 126, Proc. Supp. Mar. 1999, abstract 283P.
Ongini et al,Drug. Development Research, 52 (2001), p. 379-386.
Ongini et al,Drug. Development Research, 39 (1996), p. 450-460.
Correa et al,Society for Neuroscience Abstract Viewer/Itinerary Planner, (2002), abstract 885.8.
Parsons et al, J. Neurochemistry, 65 (1995), p. 2057-2064.
Mally et al,Pharmacol. Ther., 72, 3 (1996), p. 243-250.
Ferre et al,Curr. Med. Chem.—Central Nervous System Agents, 3 (2003), p. 1-26.
Richter, Angelika et al., “Effects of adenosine receptor agonists and antagonists in a genetic animal model of primary paroxysmal dystonia”, British Journal of Pharmacology, 134:343-352 (2001).
Del Carmen Parra Cid, M. et al., “A New Derivate of the Xanthine: A15Bu Improve The Motor Function”, Society for Neuroscience 2002 Abstract Viewer and Itinerary Planner, Program No. 165. 15.
De Sarro, G. et al., “Repeated treatment with adenosine A1 receptor agonist and antagonist modifies the anticonvulsant properties of CPPene”, European Journal of Pharmacology 317:239-245 (1996).
Khan, G. M. et al., “Anticonvulsant effect and neurotransmitter modulation of focal and systemic 2-chloroadenosine against the development of pilocarpine-induced seizures”, Neuropharmacology 39:2418-2432 (2000).
Seubert, C. N. et al., “Midazolam Selectively Potentiates the A2A—but not A1-receptor-mediated Effects of Adenosine”, Anesthesiology, 92(2):567-577 (Feb. 2000).
Pond, A. et al., “Adenosine A2A Receptor Antagonists Attenuate Haloperidol-Induced Motor Impairments in Cebus Apella and Squirrel Monkeys”, Department of Neurobiology, Schering-Plough Research Institute Poster.
Coffin, V. L. et al., “Acute Extrapyramidal Syndrome in Cebus Monkeys: Development Mediated by Dopamine D2 But Not D1 Receptors1”, The Journal of Pharmacology and Experimental Therapeutics, 249(3):769-74 (1989).
Casey, D. E., “Behavioral effects of sertindole, risperidone, clozapine and haloperidol in Cebus monkeys”, Psychopharmacology 124:134-140 (1996).
Povlsen, U. J. et al., “Effects of Serotonergic and Anticholinergic Drugs in Haloperidol-Induced Dystonia in Cebus Monkeys”, Clinical Neuropharmacology 9(1):84-90 (1986).
Casey, D. E., “Serotonergic and dopaminergic aspects of neuroleptic-induced extrapyramidal syndromes in nonhuman primates”, Psychopharmacology 112:S55-S59 (1993).
Casey, D. E., “Behavioral Effects of Long-Term Neuroleptic Treatment in Cebus Monkeys”, Psychopharmacology Supplementum 2:211-216 (1985).
De Sarro, G. et al., “Effects of Adenosine receptor agonists and antagonists on audiogenic seizure-sensible DBAS/2 mice”, European Journal of Pharmacology 371:137-145 (1999).
European Search Report for Application No. EP 03 81 8838 dated Sep. 25, 2006.
Bekar, Lane, et al; “Adenosine is crucial for deep brain stimulation—mediated attenuation of tremor”, Nature Medicine, 14(1): 75-80 (2008).
Kochanek, Patrick M., et al; “Adenosine A1receptor knockout mice develop lethal status epilepticus after experimental traumatic brain injury”, Journal of Cerebral Blood Flow & Metabolism, 26(4): (2006): Abstract of article only.
Reichelt, Melissa E., et al; “Genetic Deletion of the A1Adenosine Receptor Limits Myocardial Ischemic Tolerance”, Circulation Research, 96: 363-367 (2005).
Hoffman, D.C., et al; “Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability”, Psychopharmacology, 120: 128-133 (1995).
Grzelak Michael
Hunter John
Pond Annamarie
Varty Geoffrey
Banerjee Krishna G.
Jiang Shaojia Anna
Lee William Y.
Olson Eric S
Schering Corporation
LandOfFree
Adenosine A 2a receptor antagonists for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Adenosine A 2a receptor antagonists for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adenosine A 2a receptor antagonists for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4014322